Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

13.67
-0.4500-3.19%
Post-market: 13.41-0.2600-1.90%17:20 EDT
Volume:1.20M
Turnover:16.48M
Market Cap:1.19B
PE:-7.31
High:14.13
Open:13.75
Low:13.34
Close:14.12
52wk High:36.26
52wk Low:2.86
Shares:87.16M
Float Shares:71.89M
Volume Ratio:0.45
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8700
EPS(LYR):-1.8700
ROE:-36.61%
ROA:-21.42%
PB:2.49
PE(LYR):-7.31

Loading ...

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Dow Jones
·
Nov 19, 2025

Positive Outlook for Olema’s OPERA-02 Study Following Roche’s Successful Phase 3 Trial Results

TIPRANKS
·
Nov 19, 2025

Stock Track | Olema Pharmaceuticals Soars 139.79% Following Roche's Breast Cancer Study Success and JPMorgan's Bullish Stance

Stock Track
·
Nov 19, 2025

Stock Track | Olema Pharmaceuticals Soars 140% on JPMorgan Upgrade and Positive Industry News

Stock Track
·
Nov 19, 2025

Positive Outlook on Olema Pharmaceuticals’ Palazestrant Driven by Promising Trial Data and Market Potential

TIPRANKS
·
Nov 19, 2025

Olema Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Nov 18, 2025

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Benzinga_recent_news
·
Nov 18, 2025

Olema Rocketed 167%, Triggering A Circuit Breaker, JPMorgan's Bullish Price Target Hike

Stock Track
·
Nov 18, 2025

Stock Track | Olema Pharmaceuticals Skyrockets 208.80% Pre-Market on JPMorgan's Bullish Price Target Hike

Stock Track
·
Nov 18, 2025

Olema Oncology price target raised to $32 from $29 at JPMorgan

TIPRANKS
·
Nov 18, 2025

Oppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Nov 11, 2025

Promising Developments and Strategic Collaborations Boost Olema Pharmaceuticals’ Buy Rating

TIPRANKS
·
Nov 11, 2025

Optimistic Buy Rating for Olema Pharmaceuticals Driven by Unique Phase III Trials and Promising Market Potential

TIPRANKS
·
Nov 11, 2025

Olema Pharmaceuticals Q3 EPS $(0.49) Misses $(0.45) Estimate

Benzinga
·
Nov 10, 2025

Olema Pharmaceuticals posts Q3 net loss of $42.2 million on higher R&D spending

Reuters
·
Nov 10, 2025

BRIEF-Olema Pharmaceuticals Q3 Net Income USD -42.217 Million

Reuters
·
Nov 10, 2025

Olema Pharmaceuticals Q3 Income From Operations USD -45.877 Million

THOMSON REUTERS
·
Nov 10, 2025

Press Release: Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Dow Jones
·
Nov 10, 2025

Olema Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
Nov 08, 2025

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Nov 05, 2025